TD Ameritrade Network artwork

New Treatment For Painful Diabetic Neuropathy: Nevro (NVRO) Overview

TD Ameritrade Network

English - July 22, 2021 18:41 - 6 minutes - 34.9 MB - ★★★★★ - 11 ratings
News Commentary News Business News business news news commentary news Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed


The FDA recently approved Nevro (NVRO) treatment for chronic pain from Painful Diabetic Neuropathy (PDN). The treatment is called HFX™ and is now the only spinal cord stimulation system treatment for PDN that is approved by the FDA. Keith Grossman, Chairman and CEO of Nevro, discusses HFX™, as well as what this treatment means for diabetic patients. Nevro stock also hit an all-time high in December 2020. Tune in to find out more.